XML 59 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Fair Value Measurements (Additional Information) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2023
Apr. 30, 2023
Nov. 30, 2022
Jun. 02, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Subsidiary, Sale of Stock [Line Items]                
Oramed note discount rate         13.05%      
Aggregate Principle amount of issued debt   $ 25,000            
Warrants outstanding         6,854,309 6,899,988    
Change in fair value of debt and liability instruments         $ 4,400      
(Gain) loss on derivative liability         (512) $ 8,310 $ (300)  
Liabilities, Fair Value Adjustment       $ 30,400        
Risk Adjusted Net Sales Forecast               6.10%
Debt Securities, Available-for-Sale, Weighted Average Yield               21.50%
Common stock upon conversation of cash         $ 3,000      
Discount rate of FDA         10.20%      
Development Milestone Payment         $ 200 200    
Derivative warrant liability private warrants         1,500      
Warrants [Member]                
Subsidiary, Sale of Stock [Line Items]                
(Gain) loss on derivative liability         500 $ 8,300 $ (300)  
Oramed Note                
Subsidiary, Sale of Stock [Line Items]                
Estimated fair value         104,100      
Aggregate Principle amount of issued debt $ 101,900              
Change in fair value of debt and liability instruments         $ 2,800      
Private Placement [Member]                
Subsidiary, Sale of Stock [Line Items]                
Warrants outstanding         3,613,383      
Derivative warrant liability private warrants     $ 2,500